Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in Combination with IGAN’s IgA Protease for the Treatment of IgA Nephropathy
October 08, 2020 16:05 ET
|
Selecta Biosciences, Inc.
Application of ImmTOR™ plus IGAN’s IgA protease to target immunoglobulin A (IgA) deposition, the critical event leading to IgA Nephropathy (IgAN) Selecta’s IgA nephropathy program builds upon...
Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Supporting the Potential for Important Clinical Improvement in Patients with Chronic Refractory Gout
September 30, 2020 16:15 ET
|
Selecta Biosciences, Inc.
All data consistent with stronger performance of SEL-212 versus pegloticase Numerically higher response rate for SEL-212 versus pegloticase during primary endpoint of months 3 and 6 combined;...
Selecta Biosciences to Participate in Upcoming Investor Conferences
September 24, 2020 16:17 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
First Patient Randomized in the Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory Gout
September 23, 2020 07:00 ET
|
Selecta Biosciences, Inc.
STOCKHOLM, Sweden and WATERTOWN, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced the...
Selecta Biosciences to Participate in Upcoming Investor Conferences
September 08, 2020 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Valley Bank
September 01, 2020 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
August 06, 2020 07:30 ET
|
Selecta Biosciences, Inc.
Closed strategic licensing agreement with Sobi for SEL-212 for $100 million in initial payments and up to $630 million in potential milestones, and tiered double-digit royaltiesEntered into research...
Selecta Biosciences Appoints Peter G. Traber, MD as Chief Medical Officer
August 03, 2020 16:05 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Participate in Upcoming Investor Conferences
August 03, 2020 08:15 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter Financial Results and Recent Operational Highlights
July 30, 2020 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...